Exploring how SUMO modifications can improve cancer therapy
SUMO Modification and Cancer Therapy
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11083642
This study is looking at how certain changes in proteins can help make cancer treatments work better, especially for tough cases like colorectal cancer that don't respond well to current therapies, and it's for anyone interested in improving cancer care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11083642 on ClinicalTrials.gov |
What this research studies
This research investigates the role of SUMO modifications in cancer therapy, focusing on how these modifications can be targeted to enhance treatment effectiveness. The approach involves studying specific enzymes that activate SUMO modifications and their potential to reduce drug resistance in cancer treatments. By using animal models and examining the molecular mechanisms involved, the research aims to develop new strategies to boost anti-tumor immunity, particularly in challenging cases like immune cold colorectal cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with colorectal cancer, especially those who have not responded well to existing treatments.
Not a fit: Patients with cancers that do not involve SUMO modifications or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that overcome drug resistance and improve patient outcomes.
How similar studies have performed: Previous studies have shown promise in targeting Ubl modifications for cancer therapy, indicating that this approach could be a significant advancement in treatment options.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, YUAN — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: CHEN, YUAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy